Willis, M., Nilsson, A., Kellerborg, K., Ball, P., Roe, R., Traina, S., . . . Newell, I. (2020). Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. Diabetes Ther.
Citação norma ChicagoWillis, Michael, Andreas Nilsson, Klas Kellerborg, Philip Ball, Rupert Roe, Shana Traina, Rebecca Beale, and Isabelle Newell. "Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients With Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model." Diabetes Ther 2020.
Citação norma MLAWillis, Michael, et al. "Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients With Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model." Diabetes Ther 2020.